Bavarian Nordic owns a broadly applicable MVA-BN® vaccine
platform technology, which can be applied to develop multiple
vaccines across various disease areas, tested in more than 3,400
persons.
We can offer out-licensing opportunities of our proprietary
technologies and/or vaccine programmes and we search for
innovative technologies supplementing our in-house technologies and
programmes.
We are also interested in research collaborations with academic
groups and biotech companies. We might be able to provide
technologies and production know-how that your organization can use
to explore scientific arenas that lay beyond your available
resources and skills.
